pipette
ESEspañol

In silico designed small molecule targets misfolded TDP-43 to rescue function and ALS pathology

M. Kokes, D. S. Korumilli, V. Seawright, S. Arya, A. van Hummel, M. Sabale, M. A. Haque, N. Moreno, A. Limon, P. Ganguly, E. Shao, Y. D. Ke, R. Kayed, J.-E. Shea, A. Singh, L. Whitehead, C. Planey, V. Mathur

PreprintBold claims, read criticallyClaims a big stepReal-world use

In the authors' words

The DNA/RNA binding protein TARDBP or TDP-43 is a key driver of pathology in Amyotrophic Lateral Sclerosis (ALS), a motor neuron disease with no known cure. In >97% of sporadic ALS patients, nuclear TDP-43 in motor neurons mislocalizes and aggregates in the cellular cytoplasm (gain-of-function). A parallel reduction in nuclear TDP-43 in ALS patients leads to a loss-of-function in mRNA binding and splicing regulation. Using our machine learning platform, we discovered ACE-339, a novel, orally bioavailable small molecule that disrupts insoluble TDP-43 aggregates. Using in vitro, in vivo and in silico models, we show that ACE-339 directly targets aggregated forms of TDP-43. ACE-339 interacts directly with TDP-43 hexamers, disaggregates recombinant TDP-43 and rescues both gain- and loss-of-function phenotypes of TDP-43 in cells. ACE-339 functionally rescues TDP-43 dependent mis-splicing and synaptic activity. Lastly, ACE-339 rescues disease associated phenotypes in two independent mouse models of TDP-43 pathology. In addition, we now have a catalog of TDP-43 disaggregating compounds that are being developed further to be tested in clinical trials in patients with ALS and other TDP-43 proteinopathies.

Main resultThe abstract does not state a limitation.

Appeared: Wednesday, November 18. bioRxiv. Preprint, not yet peer-reviewed.

DOI: 10.64898/2026.11.14.766688